Sugi Predict

Sugi Predict / Targets / F2R

F2R

Proteinase-activated receptor 1 · P25116 · F2R on Sugi Atlas →

27,696 patent compounds predicted against F2R, 14,182 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
Vorapaxar Vorapaxar (SCHEMBL471187) 1.00 20/20
SCHEMBL471257 SCHEMBL471257 1.00 20/20
SCHEMBL486320 SCHEMBL486320 0.72 20/20
SCHEMBL471676 SCHEMBL471676 0.67 20/20
SCHEMBL471689 SCHEMBL471689 0.62 20/20
SCHEMBL471183 SCHEMBL471183 0.56 20/20
SCHEMBL471191 SCHEMBL471191 0.53 20/20
SCHEMBL471722 SCHEMBL471722 0.51 19/20
SCHEMBL486312 SCHEMBL486312 0.75 18/20
SCHEMBL486536 SCHEMBL486536 0.73 18/20
SCHEMBL485924 SCHEMBL485924 0.64 17/20
SCHEMBL485965 SCHEMBL485965 1.00 16/20
SCHEMBL486133 SCHEMBL486133 1.00 15/20
SCHEMBL486313 SCHEMBL486313 1.00 15/20
SCHEMBL485929 SCHEMBL485929 0.84 15/20
SCHEMBL485931 SCHEMBL485931 0.80 15/20
SCHEMBL486123 SCHEMBL486123 0.78 15/20
SCHEMBL485758 SCHEMBL485758 0.74 15/20
SCHEMBL640569 SCHEMBL640569 0.66 15/20
SCHEMBL643116 SCHEMBL643116 0.66 15/20

Clinical trials — most relevant to F2R by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Vorapaxar on Thrombin Generation and Coagulability PHASE4COMPLETED
Vorapaxar in Patients With Prior Myocardial Infarction Treated With Prasugrel and Ticagrelor PHASE4COMPLETED
Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases PHASE4COMPLETED
Vorapaxar in the Human Endotoxemia Model PHASE4COMPLETED
Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus PHASE4COMPLETED
Pharmacogenomics of Antiplatelet Response - I PHASE4COMPLETED
The Effect of Local Tranexamic Acid on Post-operative Edema and Ecchymosis in Eyelid Surgery PHASE4UNKNOWN
Bradykinin Receptor Antagonism During Cardiopulmonary Bypass PHASE2/PHASE3COMPLETED
Clinical Trial With Aprotinin in the Acute Respiratory Distress Syndrome Treatment PHASE3NOT_YET_RECRUITING
Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite PHASE2/PHASE3WITHDRAWN
Targeted Anticoagulation Therapy to Reduce Inflammation and Cellular Activation in Long-term HIV Disease PHASE2COMPLETED
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection PHASE2COMPLETED
Bradykinin Receptors and Pain PHASE2COMPLETED
Safety and Efficacy of TAK-442 in Subjects With Acute Coronary Syndromes PHASE2COMPLETED
Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications PHASE1UNKNOWN
Effects of TNX-832 (Sunol cH36) in Subjects With Acute Lung Injury/Acute Respiratory Distress Syndrome PHASE1COMPLETED
Thrombin Regulated Platelet Activation nanCOMPLETED
Impact of Combination of Clopidogrel With Aspirin on Postoperative Bleeding in Coronary Surgical Patients nanCOMPLETED
PAR Regulation of Platelet Function in Diabetic Patients nanCOMPLETED
The Evaluation of Hemostasis in Hospitalized COVID-19 Patients nanUNKNOWN
Role of the Endothelium in Stroke-like Episode Among CDG Patients nanCOMPLETED
Disorders of the Acute Phase Response Following Trauma and Invasive Surgery nanENROLLING_BY_INVITATION
Assessment of the Soluble Urokinase Plasminogen Activator Receptor in Non-cardiac Surgery (SPARSE) nanCOMPLETED
SuPAR in Adult Patients With Covid-19 nanCOMPLETED
SerpinB3 Expression, PAR2 and SCCA-PD Polymorphism in Acute Respiratory Distress Syndrome nanRECRUITING
Study of the Vascular Response to Percutaneous Coronary Intervention in Patients With Non-ST-elevation Acute Coronary Syndromes Using Intravascular Blood Sampling nanWITHDRAWN
Oxidative Stress and Haemostasis Abnormalities in Cirrhosis nanUNKNOWN
Genetic Architecture of Plasma T-PA and PAI-1 nanCOMPLETED
Inflammation, Platelets and Sickle Cell Disease nanACTIVE_NOT_RECRUITING
Association of Circulating ACE2 Levels With COVID-19 nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a F2R binder may also engage these)

ProteinNameSimilarity
P56488 — 1.000 P56488 →
P30558 — 1.000 P30558 →
Q00991 — 0.999 Q00991 →
P26824 — 0.995 P26824 →
A7YY44 — 0.994 A7YY44 →
P47749 — 0.989 P47749 →
P55086 — 0.985 P55086 →
Q920E1 — 0.984 Q920E1 →
F2RL1 Proteinase-activated receptor 2 0.984 landscape →
P48042 — 0.983 P48042 →
Q8BLG2 — 0.983 Q8BLG2 →
Q2HJA4 — 0.982 Q2HJA4 →
P49650 — 0.982 P49650 →
O00254 — 0.981 O00254 →
D4A7K7 — 0.981 D4A7K7 →
P49651 — 0.981 P49651 →
Q58D85 — 0.981 Q58D85 →
P59902 — 0.980 P59902 →
P2RY1 P2Y purinoceptor 1 0.980 landscape →
O08675 — 0.979 O08675 →
B0UXR0 — 0.979 B0UXR0 →
Q9Z282 — 0.979 Q9Z282 →
P49652 — 0.978 P49652 →
Q8C131 — 0.978 Q8C131 →
A5PLE7 — 0.978 A5PLE7 →
Q5ZI82 — 0.978 Q5ZI82 →
GPR132 Probable G-protein coupled receptor 132 0.978 landscape →
P34996 — 0.978 P34996 →
LPAR4 Lysophosphatidic acid receptor 4 0.978 landscape →
B5X337 — 0.977 B5X337 →